Section Arrow
ALMS.NASDAQ
- Alumis Inc.
Quotes are at least 15-min delayed:2026/04/07 16:05 EDT
After Hours
Last
 22.31
-- (--)
Bid
22.29
Ask
22.3
High 22.31 
Low 22.31 
Volume 23.69K 
Regular Hours (Closed)
Last
 22.29
+0.35 (+1.60%)
Day High 
22.31 
Prev. Close
21.94 
1-M High
28.44 
Volume 
1.12M 
Bid
22.29
Ask
22.3
Day Low
21.0001 
Open
21.71 
1-M Low
19.86 
Market Cap 
2.79B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.26 
20-SMA 24.6 
50-SMA 26.19 
52-W High 30.6 
52-W Low 2.7601 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.86/-3.01
Enterprise Value
2.82B
Balance Sheet
Book Value Per Share
2.37
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
24.05M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1522+0.0647+73.94%-- 
After Hours 0.1925 -- --
SILOSilo Pharma0.515+0.1592+44.74%-- 
After Hours 0.5023 -0.0279 -5.26%
LNAILunai Bioworks Inc.0.400599+0.118599+42.06%-- 
After Hours 0.39 -0.0041 -1.04%
CUECue Biopharma0.1872+0.0102+5.76%-- 
After Hours 0.1836 -- --
TERNTerns Pharmaceuticals52.635-0.145-0.27%-- 
After Hours 52.62 -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005,a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.